NewAmsterdam Pharma (NAMS) Expected to Announce Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is expected to release its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.41) per share and revenue of $4.5420 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 9:30 AM ET.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The firm had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. On average, analysts expect NewAmsterdam Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $37.95 on Monday. The firm’s 50-day simple moving average is $30.16 and its 200-day simple moving average is $23.79. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $41.47. The firm has a market cap of $4.27 billion, a P/E ratio of -23.43 and a beta of 0.05.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a “neutral” rating and a $27.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, August 25th. They set an “overweight” rating and a $45.00 target price on the stock. Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $43.20.

Insider Activity

In other news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total value of $3,874,500.00. Following the completion of the transaction, the chief accounting officer owned 15,000 shares in the company, valued at approximately $387,450. The trade was a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James N. Topper bought 1,260 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was purchased at an average price of $24.99 per share, with a total value of $31,487.40. Following the purchase, the director directly owned 3,027,864 shares of the company’s stock, valued at $75,666,321.36. The trade was a 0.04% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 2,391 shares of company stock worth $58,424 and sold 226,342 shares worth $5,748,019. 20.84% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently modified their holdings of NAMS. The Manufacturers Life Insurance Company increased its holdings in shares of NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after purchasing an additional 544 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of NewAmsterdam Pharma by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 29,277 shares of the company’s stock valued at $530,000 after purchasing an additional 1,257 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of NewAmsterdam Pharma by 5.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,383 shares of the company’s stock valued at $568,000 after purchasing an additional 1,604 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of NewAmsterdam Pharma in the second quarter valued at approximately $662,000. Finally, Legal & General Group Plc increased its holdings in shares of NewAmsterdam Pharma by 33.5% in the second quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock valued at $801,000 after purchasing an additional 11,106 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.